Experience with the approved CAR-T drugs from Novartis and Gilead has shown that being able to manufacture enough products fast enough is a major issue when it comes to marketing these cutt
Getting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a conference heard details of a cutting-edge approach that could inform clinical trials in the future.
Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering t